Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars

Amgen AMGN and Watson Pharmaceuticals, Inc. WPI announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients.